Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 651 - 700 out of 129,800

Document Document Title
WO/2017/223566A1
Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising naltrexone are provided. Formulations and methods of treating alcohol use disorder and related conditions with t...  
WO/2017/219087A1
The present invention relates to new multi-functional compounds that are useful in the treatment of neurodegenerative diseases, such as Alzheimer's disease, to the preparation of the compounds, and to compositions including the compounds...  
WO/2017/221127A1
The present disclosure refers to a compound of formula (I) in which R1 is chosen from the group consisting of (ii), (iii), (iv), (v), wherein R and R' are independently selected from the group consisting of H, CH3, Cl, Br, F, I, OCH3, CF...  
WO/2017/220053A1
The present invention relates to the use of pharmaceutical compositions containing the basic form of recombinant human erythropoietin (rhEPO) as an active ingredient, which are administered via the nasal route, in the treatment of spinoc...  
WO/2017/219500A1
Provided is a pyrimidine compound as shown in formula I, a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof. The pyrimidine compound can inhibit the activation or resistant mutation of one or more EGFRs, c...  
WO/2017/222083A1
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein n, X1, X2, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12and R13 are as defined in the specification, processes for their p...  
WO/2017/219086A1
The present invention relates to new multi-functional compounds that have a beneficial influence on biological processes involved in the ageing process, to the preparation of the compounds, and to compositions including the compounds. Th...  
WO/2017/219081A1
This invention relates to peptides and their use for modulating sodium channels. More particularly, the present invention relates to peptides from the venom of the tarantula Pamphobeteus nigricolor and their use in methods of inhibiting ...  
WO/2017/220544A1
The invention relates to a compound of formula (I) wherein R wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.  
WO/2017/221886A1
Provided are an intestinal environment-improving agent containing as an active ingredient a compound represented by formula [I] or a pharmaceutically acceptable salt thereof, and a novel medicine useful in the prevention or treatment of ...  
WO/2017/222040A1
The present invention provides a pharmaceutical composition which can be administered to a human body safely and is effective for the treatment of PolyQ diseases. The present invention provides: a pharmaceutical composition which contain...  
WO/2017/220517A1
The invention relates to a compound of formula (I) wherein R1 to R4 and n are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.  
WO/2017/220831A1
The invention relates to carbosilane dendrimers comprising polyphenol groups, and uses of same. The invention describes carbosilane dendrimers containing polyphenol groups within the structures thereof. In addition, the invention relates...  
WO/2017/220799A1
The invention concerns compounds that possess a high affinity at 5-HT 1A receptors and an agonist efficacy, as measured by Emax values from a cellular activation assay, that is higher than that of the compounds described in prior art. Th...  
WO/2017/223427A1
Materials and methods for modulating protease activated receptor 2 (PAR2) activity in order to alter myelination or demyelination are provided herein.  
WO/2017/215679A2
Disclosed are a pharmaceutical composition of chlorambucil and medical uses thereof to counter depression. The present pharmaceutical composition of chlorambucil contains chlorambucil and a natural-product compound (1) extracted from the...  
WO/2017/218957A1
The present invention provides solid state forms of certain spiro-oxindole compounds, such as funapide and the racemic mixture of funapide and its corresponding (R) enantiomer, pharmaceutical compositions comprising the solid state forms...  
WO/2017/215679A3
Disclosed are a pharmaceutical composition of chlorambucil and medical uses thereof to counter depression. The present pharmaceutical composition of chlorambucil contains chlorambucil and a natural-product compound (1) extracted from the...  
WO/2017/215524A1
Provided are an anti-human IL-17A monoclonal antibody, and a preparation method and a use thereof. The anti-human IL-17A monoclonal antibody can specifically bind to human IL-17A and has a good effect for inhibiting the secretion of infl...  
WO/2017/218886A1
The invention relates to compounds, compositions and methods for activating, reactivating, reversing or preventing the deactivation of cholinesterases, such as acetylcholinesterase and butyrylcholinesterase.  
WO/2017/218551A1
The present disclosure provides a method of treating a neurodegenerative disorder, the method comprising administering a DNA methyltransferase inhibitor.  
WO/2017/218825A1
DNA-targeted nanocarriers for encapsulating an active agent and delivering it to extracellular DNA are provided. The nanocarriers, for example, polymeric particles, liposomes, and multilamellar vesicles have targeting moiety that targets...  
WO/2017/218905A1
Described herein are methods and compositions for the use of treating Spinal Muscular Atrophy (SMA). Aspects of the invention relate to administering to a subject in need thereof an agent that inhibits muscarinic acetylcholine receptor. ...  
WO/2017/214725A1
A method of screening a compound or a composition for use in modulating opioid withdrawal symptoms in a mammal. The method comprises the steps of: selecting a group of test animals; separating the group into two subgroups; inducing panne...  
WO/2017/218519A1
The invention provides, in part, compositions and methods for treating neuronal ceroid lipofuscinoses (NCL). The invention further provides, in part, gene therapy compositions and methods for the treatment, prevention, or amelioration of...  
WO/2017/216362A1
Described are methods for producing cannabinoid prodrugs using enzyme-catalysed synthesis / chemical modifications as well as methods for formulating such prodrugs in a pharmaceutically acceptable form and their use as therapeutic agents...  
WO/2017/216792A1
Compounds represented by Formula I are disclosed herein, wherein R, Ra and R1-R14 are as defined herein. Further disclosed are uses and methods utilizing said compounds for use in inhibiting an activity of PERK, and in treating a disease...  
WO/2017/215636A1
Provided are a diaryl sulphide piperazine compound and a preparation method and a use thereof. In particular, the compound is a compound shown by formula (I), wherein HX is a C10-20 fatty acid or pamoic acid.  
WO/2017/216771A3
Methods and systems for targeted genomic modification within a target genome region (TGR) in a mammalian cell. In particular, there is provided a CRISPR/Cas9 system comprising: one or more guide RNA (gRNA) comprising a CRISPR RNA (crRNA)...  
WO/2017/218518A1
Compositions and methods for treatment of acute and chronic pain are disclosed herein. These compositions include fixed dose oral formulations containing an atypical antipsychotic drug and an opioid. Also provided here are methods of tre...  
WO/2017/215722A1
The invention relates to a composition for treating or preventing the development of emotion and/or mood disorders in a human individual, such as anxiety or depression. The human is a patient having obesity coupled with a metabolic risk ...  
WO/2017/218815A1
Disclosed herein are methods and compounds for treating a motor-associated neurodegenerative disease or condition. In some instances, also included herein are methods and compounds for treating a TDP-43 associated neurodegenerative disea...  
WO/2017/218950A1
The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease o...  
WO/2017/215600A1
Provided are a substituted tricyclic herteocyclic compound of formula I or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt, ester or a prodrug thereof, a pharmaceutical compo...  
WO/2017/218963A1
Methods and pharmaceutical compositions for use in treating diseases associated with insufficient activity of the pantothenate kinase enzyme (e.g., CASTOR diseases) are disclosed. The methods and compositions involve an effective amount ...  
WO/2017/217545A1
The present invention provides a plexin binding regulator comprising a cyclic peptide having an Arg-Trp-Thr structure or a Leu-Ser-Trp structure or a pharmaceutically acceptable salt thereof.  
WO/2017/214940A1
A lentiviral expression vector for specifically promoting high expression of a Cplx2 gene comprises a fundamental sequence, a resistance gene sequence, a multiple-cloning-sites sequence, a promoter sequence, and a Cplx2 gene cDNA sequenc...  
WO/2017/216661A1
The present invention relates to a process for the preparation of 7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy} quinolin-2(1H)-one (brexpiprazole) from 7-(4-chlorobutoxy)quinolin-2(1H)-one and 1-(benzo[b]thiophen-4-yl)piperazine. ...  
WO/2017/216813A1
The invention relates to a composition to reduce DNA and hepatic damage and to enhance repair thereof. More particularly the invention relates to a synergistic composition comprising combination of active ingredients which can be used in...  
WO/2017/215602A1
Provided in the present invention is a use of doxycycline in the preparation of a medicine for treating or preventing aging diseases, wherein the doxycycline is administered at a dose of less than 2 μg/ml, and the aging diseases mainly ...  
WO/2017/218632A1
The invention relates to devices and methods for detecting the presence of antibodies to folic acid in a sample.  
WO/2017/216771A2
Methods and systems for targeted genomic modification within a target genome region (TGR) in a mammalian cell. In particular, there is provided a CRISPR/Cas9 system comprising: one or more guide RNA (gRNA) comprising a CRISPR RNA (crRNA)...  
WO/2017/217556A1
The purpose of the present invention is to provide a medicine for preventing or treating TGFβ-related diseases by inhibiting signal transduction of TGFβ. Provided are: a TGFβ inhibitor that contains, as an active ingredient, the REIC/...  
WO/2017/218843A1
The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof. (Formu...  
WO/2017/218681A1
The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symp...  
WO/2017/215591A1
Methods for treating central nervous system (CNS) disorders or attenuating pain with a lithium benzoate compound.  
WO/2017/212420A1
The present disclosure relates to methods and compositions for managing neuroinflammation and neuroinflammation mediated neurodegenerative disease or disorder.  
WO/2017/212414A1
Compounds of Formula (I) able to modulate Store Operated Calcium Entry (SOCE). The disclosure also relates to the use of compounds of formula (I) for treatment of pathological conditions in which SOCE modulation might be beneficial, such...  
WO/2017/214286A1
Disclosed are compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and pharmaceutical compositions for treating a subject in need thereof. The disclosed compounds may be described as substit...  
WO/2017/211274A1
Provided are the use of lipids bearing fatty acids with an odd number of carbon atoms as pharmaceuticals or nutritional supplement. In particular, such lipids are used in the treatment and/or prevention of neurodegenerative diseases, opt...  

Matches 651 - 700 out of 129,800